The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN Cell Injection) for the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P).
Clinical trial NCT07617012 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07617012
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-15
- Primary completion
- 2026-08-30
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.